
    
      This study is a randomized,double-blind,placebo-controlled, investigation to evaluate the
      safety, tolerability, pharmacokinetics and the potential immunological reaction of single of
      NL005 administered intravenously to healthy volunteers.

      In Phase 1A, Seven (7) cohorts of subjects (first two cohorts 2 subjects respectively, 10
      subjects per cohort for next 5 cohorts) will administered one dose of NL005 or placebo in a
      4:1 ratio. Dosing start at 0.05μg/kg and advance to 0.25, 0.5, 2, 5, 12.5, 25μg/kg.

      NL005 or placebo administered as a single dose on Day 1. Safety parameters recorded on Study
      Days 1, 2, 5, 14, and 28. Evaluation of adverse events performed throughout the study.
      Pharmacokinetic samples obtained on Study Day 1. Blood samples collected for serum antibody
      determinations at Screening , Days 14 and 28.
    
  